CAMBRIDGE, Mass .– (COMMERCIAL THREAD) – Foundation Medicine, Inc. today announced that the company has signed Network Provider Status Agreements with Humana Military and Health Net Federal Services, which administer the TRICARE health program for the military, retirees and their families (TRICARE).1.2 TRICARE is one of the largest health plans in the United States with 9.6 million beneficiaries. Under the new agreements, TRICARE beneficiaries now have better access to FDA-approved full genomic profiling (CGP) assays, FoundationOne®CDx and FoundationOne®Liquid CDx, according to their approved indications for all solid tumors.
Using tissue or blood samples, FoundationOne CDx and FoundationOne Liquid CDx assess over 300 genes known to stimulate cancer growth and identify patients who may be eligible for targeted therapies, immunotherapies or clinical trials specific. Networked coverage of FoundationOne CDx and FoundationOne Liquid CDx tests will promote greater access to precision cancer care and may result in reduced out-of-pocket costs for patients who receive such tests in accordance with their TRICARE policy.
“We believe that all patients living with advanced cancer should benefit from comprehensive genomic profiling to inform their care and these agreements are an important step forward in achieving this through better access to testing,” said Brian Alexander, MD, MPH, Managing Director of Medicine Foundation. “We are proud to work with Humana Military and Health Net Federal Services to ensure that military personnel, retirees and their families have access to these essential clinic tools and therefore can assess potential treatment options for their specific cancer. ”
As two regional contractors of TRICARE, Humana Military and Health Net Federal Services administer care and manage the large regional networks of civilian and community providers. The TRICARE program brings together the health care resources of the Military Health System (MHS), including military hospitals and clinics, with a network of civilian health care providers, and provides significant benefit to military beneficiaries, including active duty military personnel and their families. , as well as retired military personnel and their families. Foundation Medicine’s agreements with Humana Military and Health Net Federal Services will help provide precision medicine treatment options to more cancer patients across the country.
About FoundationOne Liquid CDx
FoundationOne Liquid CDx is a next-generation qualitative sequencing-based in vitro diagnostic test for prescription use only that uses high-throughput hybridization-based targeted capture technology to analyze 324 genes using cell-free circulating DNA (cfDNA) isolated from plasma derived from anticoagulated devices. whole blood from patients with advanced cancer. The test is approved by the FDA to report short variants in over 300 genes and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 for Intended Use) according to the labeling of the approved therapeutic product. Additional genomic findings may be reported and are not prescriptive or conclusive for the labeled use of a specific therapeutic product. Use of the test does not guarantee that a patient will be matched to a treatment. A negative result does not exclude the presence of an alteration. Patients who are negative for companion diagnostic mutations should be tested for tumor tissue and the status of genomic alteration confirmed using an FDA-approved tumor tissue test, if possible. For the full label, including associated diagnostic indications and complete risk information, please visit www.F1LCDxLabel.com.
About FoundationOne CDx
FoundationOne CDx is a next-generation sequencing-based in vitro diagnostic device for the detection of substitutions, insertion and deletion alterations (indels) and copy number alterations (CNA) in 324 genes and certain rearrangements of genes, as well as genomic signatures, including microsatellite instability (MSI) and tumor mutational load (TMB) using DNA isolated from formalin-fixed and paraffin-embedded tumor tissue samples ( FFPE). FoundationOne CDx is for prescription use only and is intended as a companion diagnostic to identify patients who may benefit from treatment with certain targeted therapies according to the labeling of their approved therapeutic product. Additionally, FoundationOne CDx is intended to provide a tumor mutation profile for use by qualified healthcare professionals in accordance with professional oncology guidelines for patients with solid malignancies. Use of the test does not guarantee that a patient will be matched to a treatment. A negative result does not exclude the presence of an alteration. Some patients may require a biopsy. For a complete list of targeted therapies for which FoundationOne CDx is indicated as a companion diagnostic, please visit http://www.foundationmedicine.com/genomic-testing/foundation-one-cdx.
About Foundation Medicine
Foundation Medicine is a molecular information company dedicated to transforming cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. Foundation Medicine offers a comprehensive suite of comprehensive genomic profiling assays to identify molecular alterations in a patient’s cancer and link them with targeted therapies, immunotherapies and relevant clinical trials. Foundation Medicine’s Molecular Information Platform aims to improve daily patient care by meeting the needs of clinicians, academic researchers, and drug developers to advance the science of molecular medicine in the treatment of cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@ATCG Foundation).
Medecine® Foundation is a registered trademark of Foundation Medicine, Inc
Source: Medicine Foundation